Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Aug 17;214(9):1438–1448. doi: 10.1093/infdis/jiw372

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.

PMC Copyright notice

Figure 4. — In addition to autotaxin, lysophosphatidic acid (LPA) levels normalize during interferon (IFN)–free direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection. A and B, Levels of autotaxin (A) and LPA subtypes 16:0, 18:1, 18:2, and 20:4 (B), with the lower level of detection of 0.05 shown in dotted line. C, Percentage of total LPA that is LPA 16:0, 18:1, 18:2, or 20:4 in 5 UD participants and 10 HCV-infected participants at baseline, week 8, and week 24 of IFN-free DAA therapy for HCV. *P < .05, **P < .01, and ***P < .001. Abbreviation: UD, uninfected donor.